Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia

Ilhami Celik1 | Esma Eryilmaz-Eren1 | Aysin Kilinc-Toker1 | Didem Eren2 | Merve Yildiz1 | Azade Kanat1 | Ulas Serkan Topaloglu2 | Seda Guzeldag3 | Mehmet Kara4 | Aysegul Ulu-Kilic5

1Department of Infectious Disease and Clinical Microbiology, Kayseri City Training and Research Hospital, Kayseri, Turkey
2Department of Internal Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey
3Department of Intensive Care Unit, Kayseri City Training and Research Hospital, Kayseri, Turkey
4Department of Pharmacology, Kayseri City Training and Research Hospital, Kayseri, Turkey
5Department of Infectious Disease and Clinical Microbiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey

Correspondence
Esma Eryilmaz-Eren, Department of Infectious Diseases and Clinical Microbiology, Kayseri City Training and Research Hospital, Kayseri, Turkey.
Email: esmaereneryilmaz@gmail.com

Abstract

Background: Respiratory failure and death are the leading causes of severe Coronavirus disease 2019 (COVID-19). Hyper-inflammation and cytokine storm cause lung damage. This study aimed to compare the low-dose and high-dose effects of tocilizumab, an IL-6 receptor antagonist.

Method: Patients with severe pneumonia and hyper-inflammation signs because of COVID-19 were included in this retrospective study. Patients receiving tocilizumab <200 mg intravenously were classified as the low-dose group, and receiving ≥200 mg as the high-dose group, and those not treated with tocilizumab as the control group. Demographic and clinical data of patients who died and survived in both low-high dose and control patients were compared. According to symptom day and radiological infiltration, patients with tocilizumab were also evaluated in two groups as early and late periods at tocilizumab administration time.

Results: A total of 160 patients were included in the study; 70 were treated with a low dose and 50 with high-dose tocilizumab. Forty patients were in the control group. Age, comorbidity and clinical features were similar in the control, low-dose tocilizumab and high-dose tocilizumab groups. The mortality rate (12.9%, 30.0%, 37.5, \( P = .008 \)) was less in the low-dose tocilizumab group. The secondary infection rate was higher in the high-dose group than in the low-dose tocilizumab and control groups (44.0%, 10.0%, 10.0%, \( P < .001 \)). Distinguishing between those patients who died and survived, age (OR: 1.1589, \( P < .001 \)), higher APACHE II scores (OR: 1.225, \( P = .001 \)) and needs for non-invasive mechanical ventilation (OR: 14.469, \( P < .001 \)) were the most critical risk factors. Low-dose tocilizumab was associated with a lower mortality rate (OR: 0.244, \( P = .012 \)).

Conclusion: The use of tocilizumab at a low dose is associated with lower secondary infections and mortality.
1 | INTRODUCTION

Globally, there have been more than 188 million confirmed cases of Coronavirus disease 2019 (COVID-19), with more than 4 million deaths have been reported from the first COVID-19 case was identified. The most common symptoms of patients with COVID-19 are fever, cough and dyspnoea. Patients may have severe pneumonia, which leads to respiratory failure and death. Severe COVID-19 patients are known to have cytokine release syndrome (CRS). IL-6, IL-2, IL-7, IL-10 and tumour necrosis factor (TNF) levels were higher in patients who need intensive care. IL-6 levels were correlated with poor clinical outcome and SARS-CoV-2 RNAemia in severely ill patients.

Tocilizumab (TCZ) is an anti-interleukin-6-receptor (IL-6R) monoclonal antibody used in rheumatological diseases. The first case in which TCZ was found effective was reported, in February 2020, in China. Guaraldi et al treated 33 patients with severe pneumonia associated COVID-19, with TCZ and reported a positive effect on survival and respiratory function compared with the control group. There are also reports claiming that the use of TCZ in the treatment of severe COVID-19 is ineffective for survival. There is no consensus yet in the literature and there are different results. TCZ-related side effects have also been reported. As a result of multiple side effects, especially secondary bacterial infections, low-dose TCZ recommendations have been attracting interest. Here, we aimed to evaluate the efficacy on clinical outcome and 28-day mortality, and side effects of low-dose TCZ compared with high doses.

2 | METHODS

2.1 | Study design and patients

This retrospective study was carried out in a tertiary hospital with a 1607 bed capacity, and 253 intensive care beds. Adult patients (>18 years old) treated with intravenous TCZ because of severe COVID-19 from 1 April 2020 to 31 December 2020 were included in this study.

TCZ treatment indications were determined as follows: lymphopenia (lymphocyte count, <0.80 × 10^9/L), high CRP levels (>40 mg/dL) and high D-dimer and ferritin levels.

The case group was defined as patients who received TCZ in addition to antiviral and supportive treatment. The age- and gender-matched control group consisted of the severe COVID-19 pneumonia patients who were followed up in the same period as the patients in the study group and had hyper-inflammation but did not use TCZ. Only antiviral and supportive treatments were given to the control group.

COVID-19 pneumonia was defined as fever and respiratory tract infection findings and the presence of one of the following: respiratory rate >30/min, defined as severe respiratory distress (dyspnoea, use of extra respiratory muscles), presence of oxygen saturation <90% in room air (PaO_2/FiO_2 < 300 in the patient receiving oxygen). Antiviral treatments were used for five days as a standard. Their doses were, respectively, favipiravir; 3200 mg loading dose followed by 1600 mg/day maintenance dose, hydroxychloroquine; 400 mg/day following 800 mg loading dose and 100 mg/day following remdesivir 200 mg loading dose. Dexamethasone 8 mg/day and methylprednisolone 1 mg/kg were administered.

Patients with absolute contraindications (neutrophils <1 × 10^9/L, platelets <100 × 10^9/L, aspartate aminotransferase (AST) >3 × upper limit of normal or severely active bacterial or opportunistic infection) were not treated with TCZ.

The patients diagnosed with cancer, undergoing any immunosuppressive therapy, mild or moderate COVID-19 clinic and intubated with COVID-19 were excluded from this study.

2.2 | TCZ use

During the pandemic, a 400 mg vial of TCZ was used. The physicians determined the dose of TCZ. Each vial was divided into two to five patients, used with a 1-hour infusion in 100 cm^2 0.9% saline. Each vial was consumed within 24 hours of opening the vial. After administration of 80 or 100 mg, a further 80 or 100 mg repeat dose was administered within 24-48 hours.
TCZ doses <200 were considered a low dose, and ≥200 as a high dose.\textsuperscript{12} TCZ administration time was determined according to thorax CT imaging and duration of symptoms. If there was ground glass and duration of symptoms <7 days, it was defined as early period; if there was paving stone or fibrotic band and duration of symptoms >7 days, it was considered the late period.\textsuperscript{15}

### TABLE 1  Comparison and outcomes of survivor and non-survivor patients

|                          | Total n = 160 (%) | Survivor n = 121 (%) | Non-survivor n = 39 (%) | P       | Multivariate analysis OR (95% CI) P |
|--------------------------|-------------------|----------------------|-------------------------|---------|-----------------------------------|
| **Age -median (min-max)**| 53 (24-65)        | 51 (24-65)           | 58 (44-65)              | .002    | 1.158 (1.066-1.257)               |
| **Male gender**          | 105 (65.6)        | 78 (64.5)            | 27 (69.2)               | .699    |                                   |
| **Comorbidities**        |                   |                      |                         |         |                                   |
| Hypertension             | 53 (33.1)         | 36 (29.8)            | 17 (43.6)               | .121    |                                   |
| Diabetes mellitus        | 38 (23.8)         | 30 (24.8)            | 8 (20.5)                | .669    |                                   |
| Coronary artery disease  | 19 (11.9)         | 11 (9.1)             | 8 (20.5)                | .084    |                                   |
| Asthma                   | 16 (10.0)         | 14 (11.6)            | 2 (5.1)                 | .361    |                                   |
| Chronic obstructive pulmonary disease | 9 (5.6) | 6 (5.0) | 3 (7.7) | .689 |                                   |
| **Symptoms**             |                   |                      |                         |         |                                   |
| Dyspnoea                 | 104 (65.0)        | 76 (62.8)            | 28 (71.8)               | .340    |                                   |
| Cough                    | 103 (64.4)        | 79 (65.3)            | 24 (61.5)               | .703    |                                   |
| Myalgia                  | 48 (30.0)         | 40 (33.1)            | 8 (20.5)                | .162    |                                   |
| Fever                    | 54 (33.8)         | 41 (33.9)            | 13 (33.3)               | 1.000   |                                   |
| APACHE II                | 8 (3-31)          | 7 (3-29)             | 12 (3-31)               | <.001   | 1.225 (1.092-1.375)               | 0.001 |
| **Infiltration**         |                   |                      |                         |         |                                   |
| Ground glass opacity     | 121 (75.6)        | 98 (81.0)            | 23 (59.0)               | .009    |                                   |
| intralobular lines-fibrosis (late-chronic) | 39 (24.4) | 23 (19) | 16 (41.0) | | |
| **Antiviral treatment**  |                   |                      |                         |         |                                   |
| Hydroxychloroquine       | 3 (1.9)           | 3 (2.5)              | –                       | 1.000   |                                   |
| Remdesivir               | 2 (1.3)           | 1 (0.8)              | 1 (2.6)                 | .429    |                                   |
| Favipiravir              | 155 (96.8)        | 117 (96.7)           | 38 (97.4)               | 1.000   |                                   |
| Corticosteroid           | 148 (92.5)        | 113 (93.4)           | 35 (89.7)               | .488    |                                   |
| Methylprednisolone       | 83 (51.9)         | 65 (53.7)            | 18 (46.2)               | .463    |                                   |
| Dexamethasone            | 65 (40.6)         | 48 (39.7)            | 17 (43.6)               | .710    |                                   |
| **Respiratory support**  |                   |                      |                         |         |                                   |
| High flow O₂             | 34 (21.3)         | 23 (19.0)            | 11 (28.2)               | .261    |                                   |
| Non-invasive mechanical ventilation | 19 (11.9) | 8 (6.6) | 11 (28.2) | .001 | 14.469 (3.437-60.908) <0.001 |
| Tocilizumab              | 120 (75.0)        | 96 (79.3)            | 24 (61.5)               | .034    |                                   |
| Low dose (<200 mg)       | 70 (43.8)         | 61 (50.4)            | 9 (23.1)                | .003    | 0.244 (0.081-0.736)               | 0.012 |
| High dose (≥200 mg)      | 50 (31.3)         | 35 (28.9)            | 15 (38.5)               | .321    |                                   |
| Tocilizumab median dose (mg) (min-max) | 160 (80-800) | 100 (80-800) | 200 (80-800) | .109 | |
| **Prognosis**            |                   |                      |                         |         |                                   |
| Secondary infection      | 33 (20.6)         | 15 (12.4)            | 18 (46.2)               | <.001   |                                   |
| Bacterial infection      | 31 (19.4)         | 14 (11.6)            | 17 (43.6)               | <.001   |                                   |
| Invasive fungal infection| 8 (5.0)           | 3 (2.5)              | 5 (12.8)                | .021    |                                   |
| Median day of hospitalisation (min-max) | 15 (5-54) | 15 (6-55) | 17 (5-34) | .584 | |
2.3 | Statistical analysis

The collected information was processed using Statistical Package for Social Sciences (SPSS) for Windows (version by 22.0). Categorical variables are expressed as numbers and percentages, and Chi-square or Fisher’s Exact Test analysis was used for comparisons. Shapiro-Wilks test and histogram analyses were performed to determine whether continuous variables show normal distribution. Non-parametric data: median (min-max), while the significance between groups was determined using Mann Whitney U test. Binary logistic regression was used to estimate odds ratios (ORs) and 95% confidence interval. In all analyses, \( P < .05 \) was considered statistically significant.

3 | RESULTS

A total of 160 patients treated for severe COVID-19 were included in the study. One hundred twenty received tocilizumab and standard therapy, and 40 were treated with standard therapy as a control group. The patients’ median age was 53 (24-65) years, and 65.6% were male. Hypertension was the most common (33.1%) comorbid disease, and dyspnoea was the most common (65.0%) symptom.

According to thorax CT, 75.6% of patients were in an early-acute phase, and 24.4% had intralobular lines or fibrosis. All patients used antiviral before TCZ or including the control group, three of them used hydroxychloroquine, and two used remdesivir. A total of 148 (92.5) patients were given steroids. Nineteen patients (11.9%) were supporting non-invasive mechanical ventilation, and 34 (21.3%) were with a high flow \( O_2 \) (Table 1).

Forty-one patients needed intubation because of respiratory failure. Thirty-nine patients (24.3%) died within 28 days after TCZ infusion. The differences between the patients who survived and did not survive are presented in Table 1. Non-survivors were statistically significantly older than survivors (\( P = .002 \)). Interlobular lines and fibrosis were more common in the non-survivor group (\( P = .009 \)) and they needed more non-invasive mechanical ventilation (\( P = .001 \)) at the time they were included in the study. The rates of secondary infection, secondary bacterial infection and secondary fungal infection within 14 days after TCZ were higher in the non-survivor group (\( P < .001, P < .001 \) and \( P = .021 \), respectively) (Table 1).

In multivariate analysis, the older age (OR: 1.158, \( P < .001 \)), higher APACHE II score (OR: 1.225, \( P = .001 \)) and the necessity of non-invasive mechanical ventilation were considered as risk factors for mortality (OR: 14.469, \( P < .001 \)). Low-dose tocilizumab was reduced mortality (OR: 0.244, \( P = .012 \)).

Subgroup analysis results were similar among patients who did not support non-invasive mechanical ventilation (\( n = 141 \)). Patients who died were more likely older (median 59.5 vs 51, \( P = .003 \)), had secondary bacterial infections (50.0% vs 10.65%, \( P < .001 \)) and fungal infections (1.8% vs 21.4%, \( P = .001 \)). In multivariate analysis, the age (OR: 1.166, \( P = .003 \)) and higher APACHE score (OR: 1.223, \( P = .002 \)) was defined as a risk factor of mortality. Low-dose tocilizumab reduced mortality (OR: 0.133, \( P = .006 \)).

Laboratory data of all patients are given in Table 2. Before TCZ infusion, C-reactive protein (CRP) and D-dimer values were higher in the non-survivor group (\( P = .010 \) and \( P = .001 \)). According to the laboratory findings evaluated on the seventh day of study; leukocyte, Secondary infection was observed in 34 (20.8%) patients within 14 days.

### 3.1 | Risk factors of mortality

### Table 2 Laboratory measures of survivor and non-survivor patients

| Laboratory measures- median (min-max) (Normal values) | Before tocilizumab infusion | Seventh day after tocilizumab |
|------------------------------------------------------|-----------------------------|-------------------------------|
| White blood cell count, x10^3/µL (4.5-10)            | Survivor (n = 96) 9.59 (1.05-28.52) | Non-survivor (n = 24) 10.11 (1.60-23.22) |
|                                                     | \( P = 1.000 \)              |                                |
| Lymphocyte count, x10^3/µL (0.8-3.2)                 | Survivor (n = 96) 0.83 (0.31-3.38) | Non-survivor (n = 24) 0.79 (0.29-2.03) |
|                                                     | \( P = .928 \)               |                                |
| Creatinine mg/dL (0.70-1.20)                         | Survivor (n = 96) 0.79 (0.27-10.0) | Non-survivor (n = 24) 0.94 (0.20-2.93) |
|                                                     | \( P = .066 \)               |                                |
| Aspartate aminotransferase, U/L (0-40)                | Survivor (n = 96) 39 (9-242) | Non-survivor (n = 24) 45 (21-140) |
|                                                     | \( P = .169 \)               |                                |
| Alanine aminotransferase, U/L (0-41)                 | Survivor (n = 96) 33 (5-374) | Non-survivor (n = 24) 31 (9-114) |
|                                                     | \( P = 1.000 \)              |                                |
| Procalcitonin, µg/mL (<0.5)                          | Survivor (n = 96) 0.13 (0.01-1.65) | Non-survivor (n = 24) 0.18 (0.01-9.00) |
|                                                     | \( P = .314 \)               |                                |
| C-reactive protein, mg/dL (0-5)                      | Survivor (n = 96) 105 (7.5-366) | Non-survivor (n = 24) 150 (18-320) |
|                                                     | \( P = .010 \)               |                                |
| Ferritin, µg/L (30-400)                              | Survivor (n = 96) 110 (33-6967) | Non-survivor (n = 24) 1097 (60-4200) |
|                                                     | \( P = .924 \)               |                                |
| D- dimer, µg/L (0-500)                               | Survivor (n = 96) 2066 (150-11 560) | Non-survivor (n = 24) 2066 (150-14 180) |
|                                                     | \( P = .001 \)               |                                |
| Fibrinogen, mg/L (2000-4000)                         | Survivor (n = 96) 7079 (2050-11 650) | Non-survivor (n = 24) 7048 (4220-10 860) |
|                                                     | \( P = .536 \)               |                                |
serum aspartate aminotransferase (AST), CRP, procalcitonin, D-dimer and fibrinogen levels were higher, and lymphocyte parameters were lower in the non-survivor group (P < .001, P = .008, P < .001, P = .001, P < .001, P = .007 and P < .001, respectively) (Table 2).

3.2 | The outcome of low- vs high-dose TCZ

Older age, demographic data, symptoms at admission, APACHE II scores, corticosteroid or antiviral treatment and respiratory support before TCZ of the patients treated with low- or high-dose TCZ and control group were similar (Table 3). Within 14 days, secondary infections and secondary bacterial infections were higher in the high-dose TCZ group than the low-dose TCZ and control groups (P < .001 and P < .001, respectively). The mortality rate was lower in the low-dose group (12.9%) than in the high-dose (30%) and control group. The difference was statistically significant (P = .008). In paired comparisons, there was a significant difference between low-dose TCZ and high-dose TCZ groups with P = .036, low-dose TCZ and control groups with P = .004.

### TABLE 3 Demographic and clinical characteristics of patients treated with low- or high-dose tocilizumab and control group

|                          | Control (n = 40 (%)) | Low dose (<200 mg) (n = 70 (%)) | High dose (≥200 mg) (n = 50 (%)) | P   |
|--------------------------|----------------------|---------------------------------|---------------------------------|-----|
| Age -median (min-max)    | 53 (41-63)           | 51 (24-65)                      | 53 (27-65)                      | .490|
| Male gender              | 21 (52.5)            | 46 (65.7)                       | 38 (76.0)                       | .660|
| Comorbidities            |                      |                                 |                                 |     |
| Diabetes mellitus        | 12 (30.0)            | 13 (18.6)                       | 13 (26.0)                       | .361|
| Hypertension             | 18 (45.0)            | 20 (28.6)                       | 15 (30.0)                       | .190|
| Coronary artery disease  | 3 (4.3)              | 4 (3.3)                         | 11 (22.0)                       | .093|
| Chronic obstructive pulmonary disease | 2 (5.0) | 3 (4.3) | 4 (3.3) | .684|
| Asthma                   | 6 (15.0)             | 5 (7.1)                         | 5 (10.0)                        | .418|
| Symptoms                 |                      |                                 |                                 |     |
| Dyspnoea                 | 27 (67.5)            | 44 (62.9)                       | 33 (66.0)                       | .872|
| Cough                    | 31 (77.5)            | 42 (60.0)                       | 30 (60.0)                       | .135|
| Myalgia                  | 13 (32.5)            | 18 (25.7)                       | 17 (34.0)                       | .573|
| Fever                    | 12 (30.0)            | 21 (30.0)                       | 21 (42.0)                       | .331|
| APACHE II                | 9.05 (±6.49)         | 9.07 (±3.68)                    | 9.42 (±3.52)                    | .898|
| Treatments               |                      |                                 |                                 |     |
| Corticosteroid           | 35 (87.5)            | 64 (91.4)                       | 49 (98.0)                       | .154|
| Methylprednisolone       | 20 (50.0)            | 35 (50.0)                       | 28 (56.0)                       | .780|
| Dexamethasone            | 16 (40.0)            | 28 (40.0)                       | 21 (42.0)                       | .972|
| Antiviral treatment      |                      |                                 |                                 |     |
| Hydroxychloroquine       | 1 (2.5)              | 2 (2.9)                         | –                               | .495|
| Favipiravir              | 39 (97.5)            | 70 (100)                        | 50 (100)                        | .221|
| Remdesivir               | 1 (1.4)              | 1 (2.5)                         | –                               | .561|
| Respiratory support before tocilizumab |              |                                 |                                 |     |
| High flow O₂             | 9 (22.5)             | 10 (14.3)                       | 15 (30.0)                       | .113|
| Non-invasive mechanical ventilation | 6 (15.0) | 7 (10.0) | 6 (12.0) | .737|
| Prognosis                |                      |                                 |                                 |     |
| Median day of hospitalisation (min-max) | 14.5 (5-49) | 15.5 (6-36) | 16 (6-52) | .402|
| Mortality 28th day       | 15 (37.5)            | 9 (12.9)                        | 15 (30.0)                       | .008|
| Secondary infection after tocilizumab | 4 (10.0) | 7 (10.0) | 22 (44.0) | .000|
| Bacterial infection      | 4 (10.0)             | 7 (10.0)                        | 20 (40.)                        | .000|
| Invasive fungal infection | –                   | 2 (2.9)                         | 6 (12.0)                        | .019|
3.3 The outcome of early vs late initiation of TCZ

Ninety (75%) of case group patients with earlier onset of symptoms and ground-glass radiological infiltration in thorax CT received TCZ infusion compared with 30 patients with later symptoms and late findings and fibrotic bands thorax CT. The characteristics of patients who received tocilizumab in the early or late period are presented in Table 4. The patients who received TCZ later were significantly older (P = .005). Gender, comorbid diseases, symptoms, antiviral and supportive treatment were similar (Table 4). More intubation was needed in the late period group was on the seventh day after treatment (36.7% vs 15.6%) (P = .02). The mortality rate with secondary bacterial infections was statistically higher among patients with late initiation (P = .035 and P = .032, respectively).

|                        | Early administration | Late administration | P   |
|------------------------|----------------------|---------------------|-----|
| Age-Median (min-max)   | n = 90 (%)           | n = 30 (%)          |     |
|                        | 51 (24-65)           | 58.5 (27-65)        | .005|
| Male gender            | 60 (66.7)            | 24 (80.0)           | .250|
| Comorbidities          |                      |                     |     |
| Diabetes mellitus      | 18 (20.0)            | 8 (26.7)            | .373|
| Hypertension           | 29 (32.2)            | 6 (20.0)            | .250|
| Coronary artery disease| 9 (10.0)             | 5 (16.7)            | .335|
| Chronic obstructive pulmonary disease | 3 (3.3) | 4 (13.3) | .065|
| Asthma                 | 7 (7.8)              | 4 (13.3)            | .464|
| Symptoms               |                      |                     |     |
| Dyspnoea               | 54 (60.0)            | 23 (76.7)           | .125|
| Cough                  | 55 (61.1)            | 17 (56.7)           | .673|
| Myalgia                | 28 (31.1)            | 7 (23.3)            | .492|
| Fever                  | 32 (35.6)            | 10 (33.3)           | .825|
| Corticosteroid         | 85 (94.4)            | 28 (93.3)           | .822|
| Methylprednisolone     | 48 (54.5)            | 15 (50.0)           | .678|
| Dexamethasone          | 36 (40.9)            | 13 (43.3)           | .833|
| Antiviral treatment before tocilizumab |                  |                     |     |
| Hydroxychloroquine     | 2 (2.0)              | 0 (0.0)             | 1.000|
| Favipiravir            | 90 (100)             | 30 (100)            | 1.000|
| Remdesivir             | 0 (0.0)              | 1 (3.3)             | .254|
| Respiratory support before tocilizumab |                  |                     |     |
| High flow O₂           | 18 (20.0)            | 7 (23.3)            | .796|
| Non-invasive mechanical ventilation | 9 (10.0) | 4 (13.3) | .735|
| Tocilizumab median dose (mg) (min-max) | 100 (80-800) | 200 (80-600) | .276|
| Low dose (<200 mg)     | 56 (62.2)            | 14 (20.0)           | .142|
| High dose (≥200 mg)    | 34 (37.8)            | 16 (53.3)           | .142|
| Prognosis              |                      |                     |     |
| Intubation after tocilizumab | 14 (15.6) | 11 (36.7) | .020|
| Median day of hospitalisation (min-max) | 15 (6-52) | 17.5 (6-34) | .366|
| Mortality 28th day     | 14 (15.6)            | 10 (33.3)           | .035|
| Secondary infection after tocilizumab | 18 (20.0) | 11 (36.7) | .065|
| Bacterial infection    | 16 (17.8)            | 11 (36.7)           | .032|
| Invasive fungal infection | 4 (4.4)  | 4 (13.3) | .106|
4 | DISCUSSION

In this study, we retrospectively evaluated the effect of different doses of TCZ on survival in patients with severe COVID-19 pneumonia. We observed that low-dose TCZ treatment when administered with low-dose and early-stage COVID-19 reduced mortality compared with those who did not receive TCZ or those who received high-dose TCZ. Also, secondary bacterial and opportunistic fungal infections were less common in the low-dose group. The most important prognostic factors affecting mortality in patients included in our study were older age, higher APACHE II and the need for non-invasive mechanical ventilation.

It is known that cytokine levels correlate with the disease severity of COVID-19. Based on this point, TCZ treatment, which is used and effective through IL-6 blockade, has different results in the literature and its efficacy remains controversial. In a meta-analysis, seven studies were evaluated and reported that TCZ treatment did not reduce mortality in the treatment of severe COVID-19. Based on this point, TCZ treatment, which is used and effective through IL-6 blockade, has different results in the literature and its efficacy remains controversial. In a meta-analysis, seven studies were evaluated and reported that TCZ treatment did not reduce mortality in the treatment of severe COVID-19. On the other hand, Rossi et al showed that early and low-dose TCZ treatment reduced mortality compared with standard therapy in COVID-19-related respiratory failure patients. In our study, the mortality rate was lower in the low-dose group than in the high-dose and control group.

Secondary infections are the most important safety concerns in treatment with TCZ. In the study by Quartuccio et al, bacterial superinfection was observed in 17 of 42 patients treated with TCZ, but none in the control group. Somers et al reported that two times more superinfections were reported in patients treated with TCZ than in the control group. In the study by Kim et al, more secondary bacterial infections were observed in patients who received TCZ compared with the control group. Also, invasive fungal infection was reported in three patients in the TCZ group. Accordingly, more deaths were reported in the TCZ group. In our cases, the secondary infection rate did not significantly result in the multi analysis but was lower in the low-dose TCZ group than in the high-dose TCZ group and control. Besides, the secondary infection rate was very high in the non-survivor group. The IL-6 level measured in patients with cytokine storm because of COVID-19 was shown to be lower than in patients with sepsis. Therefore, the use of high doses of TCZ might result in more immunosuppression than targeted. In this case, high doses of TCZ will inevitably cause secondary infections.

Older age, dyspnoea or respiratory distress, increased WBC, CRP and procalcitonin and low lymphocyte levels were previously determined to risk factors for poor prognosis. Consistent with the literature, in our study, older age and the need for non-invasive mechanical ventilation were defined as risk factors for mortality. Leukocytosis, CRP and procalcitonin were increased in non-survivor patients, and lymphocytes were decreased. Patients in the non-survivor group had higher C-reactive protein (CRP) and D-dimer values before TCZ infusion.

The most important limitation was that the IL-6 level was not measured. Based on previous studies, treatment was determined based on the idea that IL-6 levels were lower than sepsis. In addition, in the early initiation group, 56 patients were treated with low-dose TCZ, 34 patients were high-dose TCZ; in the late initiation group, 14 patients were low-dose treatment and 16 patients were high-dose treatment. In our study, when we divided patients into subgroups, the number of patients was relatively low. Another important limitation was that some clinical data, such as vasopressor dose or fluid-electrolyte balance, were not available because of the retrospective study. Further multicentre and randomised trials are needed to confirm the efficacy and safety of early administration of a low dose of TCZ in larger populations.

5 | CONCLUSION

Early (within the first seven days of symptoms onset) and low-dose TCZ appear to contribute to recovery in severe COVID-19 pneumonia patients. At this point, the rational use of TCZ is essential. Older age and the need for non-invasive mechanical ventilation are factors affecting mortality. There was a lower secondary infection with low-dose TCZ.

ETHICS

This research was approved by the local ethics committee (Date: 01.10.2020, Number: 171).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID

Ilhami Celik https://orcid.org/0000-0002-2604-3776
Esma Eryilmaz-Eren https://orcid.org/0000-0002-2712-9694
Aysegul Ulu-Kilic https://orcid.org/0000-0003-1363-3993
Seda Guzeldag https://orcid.org/0000-0002-9298-9527
Didem Eren https://orcid.org/0000-0002-9298-9527
Serdar Eren https://orcid.org/0000-0002-9298-9527
Merve Yildiz https://orcid.org/0000-0003-1363-3993
Azade Kanat https://orcid.org/0000-0003-2499-0101
Ulas Serkan Topaloglu https://orcid.org/0000-0001-6625-7763
Mehmet Kara https://orcid.org/0000-0003-0771-3740

REFERENCES

1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed July 19, 2021.
2. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422.
3. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529-539.
4. Coperchini F, Chiavoto L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32.

5. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-1310.

6. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474-e484. 10.1016/S2665-9913(20)30173-9.

7. Campochiaro C, Della-Torre E, Cavalli G, et al. TOCIRAF Study Group. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43-49. 10.1016/j.ejim.2020.05.021.

8. Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2020;S2531-0437(20):30153-30157.

9. Kimmig LM, Wu D, Gold M, et al. IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne). 2020;7:583897. 10.3389/fmed.2020.583897.

10. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. 2020;158(4):1397-1408. 10.1016/j.chest.2020.06.006.

11. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31-35. 10.1016/j.ejim.2020.05.009.

12. De Rossi N, Scarpazza C, Filippini C, Montichiari COVID-19 Study Group, et al. Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020;25:100459. 10.1016/j.eclinm.2020.100459.

13. Ministry of Health. COVID-19 (SARS-CoV-2 INFECTION) General Information, Epidemiology And Diagnosis Guide (December 7, 2020). Ankara, Turkey.

14. Ministry of Health. COVID-19 (SARS-CoV-2 INFECTION) management of severe pneumonia, ARDS, sepsis and septic shock (November 7, 2020). Ankara, Turkey.

15. Saburi A, Schoepf UJ, Ulversoy KA, Jafari R, Eghbal F, Ghanei M. From radiological manifestations to pulmonary pathogenesis of COVID-19: a bench to bedside review. Radiol Res Pract. 2020:2020;8825761. 10.1155/2020/8825761.

16. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-1028.

17. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China. Intensive Care Med. 2020;46:846-848. 10.1007/s00134-020-05991-x.

18. Lavillegar JD, Garner M, Spaeth A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care. 2021;11(1):9. 10.1186/s13613-020-00798-x.

19. Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56:106103. 10.1016/j.ijantimicag.2020.106103.

20. Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020;129:104444.

21. Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2021;73(2):e445-e454. 10.1093/cid/ciaa954.

22. Kox M, Waalders NJB, Koolstra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. 2020;324(15):1565-1567.

23. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233-1244.

24. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069. 10.1001/jama.2020.1585.

25. Han J, Shi LX, Xie Y, et al. Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration. Epidemiol Infect. 2020;148:e125.

26. Boari GEM, Chiarini G, Bonetti S, et al. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. BioSci Rep. 2020;40(12):BSR20203455. 10.1042/BSR20203455.

How to cite this article: Celik I, Eryilmaz-Eren E, Kilinc-Toker A, et al. Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia. Int J Clin Pract. 2021;75:e14997. doi:10.1111/ijcp.14997.